Consider immunotherapy as first-line treatment.Application of immunotherapy is becoming increasingly more sophisticated as we learn to control the many signals that activate and deactivate T cells. We now have two approved immunotherapies for metastatic melanoma - high-dose interleukin-2 (Proleukin) and ipilimumab (Yervoy) - and at least two investigational ones - adoptive T-cell therapy and a novel antibody to PD-1 (MDX-1106; ASCO 2010 annual meeting. Abstract 2506) - that are especially promising.There...